Evidence map›Paper›PMID 39716733›Full record

ReviewEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2024

Spotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects.

Michiel Rienstra, Stylianos Tzeis, Karina V Bunting, Valeria Caso, Harry J G M Crijns, Tom J R De Potter, Prashanthan Sanders, Emma Svennberg, Ruben Casado-Arroyo, Jeremy Dwight and 16 more

Abstract readReview
In one paragraph

Review in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Long-term efficacy and safety of left atrial appendage closure vs. oral anticoagulation in atrial fibrillation: a meta-analysis of randomized controlled trials.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Pooled it
  2. Clinical outcomes of continuing vs. discontinuing oral anticoagulation after atrial fibrillation ablation: an updated systematic review and meta-analysis of observational studies and randomized controlled trials.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Pooled it
  3. Guideline
  4. Impact of catheter ablation timing according to duration of atrial fibrillation history on arrhythmia recurrences and clinical outcomes: a meta-analysis.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Pooled it
  5. Trial
  6. Cognitive function and telemedicine-based, village doctor-led care for atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  7. Edoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  8. Cryoballoon ablation vs. antiarrhythmic drug therapy as initial treatment for persistent atrial fibrillation: the multicentre randomized CEPAF trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  9. Incident heart failure in patients with screening-detected atrial fibrillation: a post hoc analysis of the STROKESTOP and STROKESTOP II studies.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  10. Population reach and participation rate in opportunistic vs. systematic atrial fibrillation screening: STROKESTOP III.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  11. Percutaneous left atrial appendage closure following catheter ablation therapy of atrial fibrillation: outcomes stratified by bleeding risk - a sub-analysis of the OPTION study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  12. Autonomic effects and ablation success after pulsed field and cryoballoon ablation: a SINGLE SHOT CHAMPION substudy.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  13. Comparison of the effectiveness and safety of dronedarone and amiodarone for preventing recurrence after catheter ablation of atrial fibrillation: an open-label randomized controlled trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  14. Safety and effectiveness of the TactiFlex duo system: 6-month results of the FOCALFLEX study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  15. Abnormal "Frontiers in cardiovascular medicine · 2026
    Trial
  16. Association between comorbidity burden and outcomes of catheter ablation vs. medical therapy for atrial fibrillation: insights from the CABANA trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Trial
  17. Systematic, randomized atrial fibrillation screening using detailed phenotyping with a risk prediction model combined with patch electrocardiogram in a Swedish population aged 65 years or older: the CONSIDERING-AF trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Trial
  18. Impact of renal function on the efficacy of low-voltage area ablation after pulmonary vein isolation: a sub-analysis of the SUPPRESS-AF trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Trial
  19. Identifying patients at low risk for atrial fibrillation after cryptogenic stroke: the PAVA score.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Observational
  20. Article

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Michiel RienstraDepartment of Cardiology, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.ORCID 0000-0002-2581-070X
Stylianos TzeisDepartment of Cardiology, Mitera Hospital, Athens, Greece.ORCID 0000-0002-2007-1928
Karina V BuntingInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0003-4602-4377
Valeria CasoStroke Unit, Santa Maria della Misericordia-University of Perugia, Perugia, Italy.ORCID 0000-0002-2020-8891
Harry J G M CrijnsDepartment of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands.ORCID 0000-0003-1073-5337
Tom J R De PotterDepartment of Cardiology, OLV Hospital, Aalst, Belgium.ORCID 0000-0003-1424-114X
Prashanthan SandersCentre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, SA, Australia.ORCID 0000-0003-3803-8429
Emma SvennbergDepartment of Medicine Karolinska University Hospital (MedH), Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-6413-0870
Ruben Casado-ArroyoDepartment of Cardiology, H.U.B.-Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.ORCID 0000-0002-3876-6074
Jeremy DwightESC Patient Forum, Sophia Antipolis, France.
Luigina GuastiDepartment of Medicine and Surgery, University of Insubria, Varese, Italy.ORCID 0000-0002-4524-4864
Thorsten HankeClinic For Cardiac Surgery, Asklepios Klinikum, Harburg, Hamburg, Germany.ORCID 0000-0002-8481-4700
Tiny JaarsmaDepartment of Cardiology, Linkoping University, Linkoping, Sweden.ORCID 0000-0002-4197-4026
Maddalena LettinoDepartment for Cardiac, Thoracic and Vascular Diseases, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.ORCID 0000-0003-0146-9196
Maja-Lisa LøchenDepartment of Clinical Medicine, UiT, The Arctic University of Norway, Tromsø, Norway.ORCID 0000-0002-8532-6573
R Thomas LumbersInstitute of Health Informatics, University College London, London, UK.ORCID 0000-0002-9077-4741
Bart MaesenDepartment of Cardiothoracic Surgery, Maastricht University Medical Centre+, Maastricht, The Netherlands.ORCID 0000-0001-8622-1450
Inge MølgaardESC Patient Forum, Sophia Antipolis, France.
Giuseppe M C RosanoDepartment of Human Sciences and Promotion of Quality of Life, Chair of Pharmacology, San Raffaele University of Rome, Rome, Italy.ORCID 0000-0003-4023-2263
Renate B SchnabelCardiology University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0001-7170-9509
Piotr SuwalskiDepartment of Cardiac Surgery and Transplantology, National Medical Institute of the Ministry of Interior and Administration, Centre of Postgraduate Medical Education, Warsaw, Poland.ORCID 0000-0003-2670-4164
Juan TamargoPharmacology and Toxicology School of Medicine, Universidad Complutense, Madrid, Spain.ORCID 0000-0002-7979-7758
Otilia TicaInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0002-6019-122X
Vassil TraykovDepartment of Invasive Electrophysiology, Acibadem City Clinic Tokuda University Hospital, Sofia, Bulgaria.ORCID 0000-0002-9523-6416
Dipak KotechaInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0002-2570-9812
Isabelle C Van GelderDepartment of Cardiology, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.ORCID 0000-0002-7579-1201

Funding

Abbott LaboratoriesAbbott VascularAcesion PharmaAdagio MedicalAmarin CorporationAstra ZenecaAstraZenecaAtriCureBayerBayer AGBayer HealthCareBiomedical Research CentreBiosense WebsterBiotronikBioVentrixBoehringer-IngelheimBoston ScientificBoston Scientific, Medtronic, Abbott, and Becton DickensonBristol Myers SquibbBritish Heart Foundation FS/CDRF/21/21032CathRxCook and Wolstenholme Charitable TrustDaiichi SankyoDanish Heart AssociationDutch Cardiovascular AllianceDutch Heart Foundation 848090001Edwards LifesciencesERACoSysMed3 031L0239EUEU HorizonEuropean Research CouncilEuropean Society of CardiologyEVER Neuro PharmaFitfileGerman Centre for Cardiovascular Research 81Z1710103German Ministry for Research and Technology BMBF 01ZX1408AHealth Data Research UKHealthLumenHorizon 2020 847770Horizon Europe 101095480InCarda TherapeuticsInnovative Medicines InitiativeJohnson and JohnsonMedical Research CouncilMedtronicMenarini GroupMerck Sharp & DohmeNational Institute for Health Research NIHR CDF-2015-08-074 RATE-AFNetherlands Cardiovascular Research InitiativeNIH HHSNorgine BVOxford University PressPacematePassPACESPfizerPfizer Innovative Target Exploration NetworkPioneer FundR&D Subnational Secure Data Environment ProgrammeRoche DiagnosticsRoyal College of PhysiciansSanofiSt. Jude MedicalSun Wave PharmaTeva Pharmaceutical IndustriesUniversity of BirminghamVifor InternationalZonMw
6 · The paper itself

Abstract

Atrial fibrillation (AF) remains the most common cardiac arrhythmia worldwide and is associated with significant morbidity and mortality. The European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) have recently released the 2024 guidelines for the management of AF. This review highlights 10 novel aspects of the ESC/EACTS 2024 Guidelines. The AF-CARE framework is introduced, a structural approach that aims to improve patient care and outcomes, comprising of four pillars: [C] Comorbidity and risk factor management, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, and [E] Evaluation and dynamic reassessment. Additionally, graphical patient pathways are provided to enhance clinical application. A significant shift is the new emphasis on comorbidity and risk factor control to reduce AF recurrence and progression. Individualized assessment of risk is suggested to guide the initiation of oral anticoagulation to prevent thromboembolism. New guidance is provided for anticoagulation in patients with trigger-induced and device-detected sub-clinical AF, ischaemic stroke despite anticoagulation, and the indications for percutaneous/surgical left atrial appendage exclusion. AF ablation is a first-line rhythm control option for suitable patients with paroxysmal AF, and in specific patients, rhythm control can improve prognosis. The AF duration threshold for early cardioversion was reduced from 48 to 24 h, and a wait-and-see approach for spontaneous conversion is advised to promote patient safety. Lastly, strong emphasis is given to optimize the implementation of AF guidelines in daily practice using a patient-centred, multidisciplinary and shared-care approach, with the simultaneous launch of a patient version of the guideline.

Indexed as

AnticoagulantsAtrial FibrillationCatheter AblationPractice Guidelines as TopicAnti-Arrhythmia AgentsCardiologyComorbidityEuropeHumansRisk AssessmentRisk FactorsStrokeThromboembolismTreatment OutcomeAnti-Arrhythmia AgentsAnticoagulantsAtrial fibrillationGuidelinesManagement

Identifiers

PMID39716733
PMCPMC11666470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.